Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm

The objective of the study was to develop and validate a practical prognostic index for patients with amyotrophic lateral scleroses (ALS) using information available at the first clinical consultation. We interrogated datasets generated from two population-based projects (based in the Republic of Ireland and Italy). The Irish patient cohort was divided into Training and Test sub-cohorts. Kaplan–Meier methods and Cox proportional hazards regression were used to identify significant predictors of prognoses in the Training set. Using a weighted grading system, a prognostic index was derived that separated three risk groups. The validity of index was tested in the Irish Test sub-cohort and externally confirmed in the Italian replication cohort. In the Training sub-cohort (n = 117), significant predictors of prognoses were site of disease onset (HR = 1.7, p = 0.012); ALSFRS-R slope prior to first evaluation (HR = 2.8, p < 0.0001), and executive dysfunction (HR = 2.11, p = 0.001). The risk group system generated using these results predicted median survival time in the Training set, the Test set (n = 87) and the Italian cohort (n = 122) with no overlap of the 95 % CI (p < 0.0001). In the validation cohorts, a high-risk classification was associated with a positive predictive value for poor prognosis of 73.3–85.7 % and a negative predictive value (NPV) for good prognosis of 93.3–100 %. Classification into the low-risk group was associated with an NPV for bad prognosis of 100 %. A simple algorithm using variables that can be gathered at first patient encounter, validated in an independent patient series, reliably predicts prognoses in ALS patients.

[1]  M. York,et al.  Detecting frontotemporal dysfunction in ALS: Utility of the ALS Cognitive Behavioral Screen (ALS-CBS™) , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[2]  A. Al-Chalabi,et al.  Early symptom progression rate is related to ALS outcome: a prospective population-based study. , 2002, Neurology.

[3]  Adriano Chiò,et al.  The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. , 2007, Current medicinal chemistry.

[4]  O. Hardiman,et al.  Cognitive changes predict functional decline in ALS , 2013, Neurology.

[5]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.

[6]  P. Sham,et al.  Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis , 2002, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[7]  A. Al-Chalabi,et al.  Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study , 2012, The Lancet Neurology.

[8]  O. Hardiman,et al.  Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives , 2011, BMJ Supportive & Palliative Care.

[9]  Adriano Chiò,et al.  The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials , 2011, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[10]  S. Appel,et al.  Predictability of disease progression in amyotrophic lateral sclerosis , 2006, Muscle & nerve.

[11]  Adriano Chiò,et al.  Acute migraine treatment with droperidol , 2003, Neurology.

[12]  Chris Shaw,et al.  PROGNOSTIC CATEGORIES FOR AMYOTROPHIC LATERAL SCLEROSIS , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  G. Filippini,et al.  Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[14]  R. Sica,et al.  Regional spread pattern predicts survival in patients with sporadic amyotrophic lateral sclerosis , 2012, European journal of neurology.

[15]  L. Goldstein,et al.  Cognitive deficits in non-demented amyotrophic lateral sclerosis patients: a neuropsychological investigation , 1995, Journal of the Neurological Sciences.

[16]  J. Slattery,et al.  The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register , 1993, Journal of Neurology.

[17]  E. Beghi,et al.  Prognostic factors in ALS: A critical review , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[18]  A. Chiò,et al.  Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV , 2012, Neurology.

[19]  S. Appel,et al.  Amyotrophic lateral sclerosis: early predictors of prolonged survival , 2006, Journal of Neurology.

[20]  A. Chiò,et al.  Epidemiology of ALS in Italy , 2009, Neurology.

[21]  J. Martí-Fàbregas,et al.  [Prognostic factors in amyotrophic lateral sclerosis]. , 1996, Neurologia.

[22]  D. Morris,et al.  Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing , 2013, Journal of Medical Genetics.

[23]  L. H. van den Berg,et al.  Lifetime occupation, education, smoking, and risk of ALS , 2007, Neurology.

[24]  Bryan J. Traynor,et al.  An outcome study of riluzole in amyotrophic lateral sclerosis , 2003, Journal of Neurology.

[25]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[26]  O. Hardiman,et al.  Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004 , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[27]  V. Meininger,et al.  Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole , 2005, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[28]  Adriano Chiò,et al.  Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[29]  O. Combarros,et al.  Motor neuron disease in Cantabria , 1988, Acta neurologica Scandinavica.

[30]  O. Hardiman,et al.  The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[31]  M. Naumann,et al.  Disease progression in amyotrophic lateral sclerosis: Predictors of survival , 2002, Muscle & nerve.

[32]  C. Ki,et al.  Spectrum of Cognitive Impairment in Korean ALS Patients without Known Genetic Mutations , 2014, PloS one.

[33]  Elaine Niven,et al.  Screening for cognition and behaviour changes in ALS , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[34]  O. Hardiman,et al.  Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia , 2011, Neurology.

[35]  T. Hanafusa,et al.  Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS , 2006, Neurology.